Abstract

The Pharmacology Core will measure drug and/or metabolite concentrations in biological fluids of AIDS patients using established or modified assays. New """"""""state of the art"""""""" drug assays will be developed for which fundamental parameters such as specificity, sensitivity, reproducibility, and rapidity will permit pharmacokinetic studies with AIDS patients. Rigorous and continuous quality controls will be performed in order to provide objective data on the intra-day and inter-day precision and accuracy of each analytical method. This will be important for permitting quality methods for subsequent investigations. Sample libraries (""""""""Master Data Inventory"""""""" notebook and computer files) will be developed so that all samples passing through the laboratory will be entered and stored in the registration system. Data generated in the Core Laboratory will be reported to ACTU investigators and NIH officials. Results of studies performed in the Pharmacology Core Laboratory will be presented at the ACTU meetings and subsequently published.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI032775-02
Application #
3769648
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294

  Publications

Lockman, Shahin; Hughes, Michael; Sawe, Fred et al. (2012) Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 9:e1001236
Ciaranello, Andrea L; Lockman, Shahin; Freedberg, Kenneth A et al. (2011) First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 25:479-92
Boltz, Valerie F; Zheng, Yu; Lockman, Shahin et al. (2011) Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 108:9202-7
Haas, David W; Koletar, Susan L; Laughlin, Laura et al. (2009) Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 50:290-3
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-66
Twigg Iii, Homer L; Weiden, Michael; Valentine, Fred et al. (2008) Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 197:109-16
Kilby, J Michael; Lee, Ha Youn; Hazelwood, J Darren et al. (2008) Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS 22:957-62
Riddler, Sharon A; Jiang, Hongyu; Tenorio, Allan et al. (2007) A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 12:531-41
Acosta, Edward P; Kendall, Michelle A; Gerber, John G et al. (2007) Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 51:3104-10

Showing the most recent 10 out of 71 publications